News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
ChampionsGate Acquisition Corp (CHPG) reported a net income of $1.15 million for the first half of 2026, primarily from $1.36 million in interest and dividend income from its U.S. Treasury-based trust account. However, the SPAC disclosed a working capital deficit and expressed substantial doubt …
MONTRÉAL, Aug. 12, 2026 /CNW/ -- SYDNEY, August 13, 2026 - Champion Iron Limited (ASX: CIA) (TSX: CIA) (OTCQX: CIAFF) ("Champion" or the "Company") announces that, further to the various filings previously made in this regard, its Annual General Meeting of Shareholders (the "Meeting") …
Sharemaestro market context Price below Trend Line 52 weeks -16.0%This article provides an earnings forecast for Champions Oncology Inc (CSBR), noting that no earnings forecast score is currently available, but the industry average is 8.10. Analysts have set a consistent price target of $12.00, with an upside potential of over 109%. The report …
Champions Oncology (NASDAQ:CSBR) saw its stock price fall below its 200-day moving average to $5.76, amidst a downgrade from Weiss Ratings to "sell (E+)." Despite beating quarterly earnings expectations with $0.01 EPS against an anticipated $0.05 loss and revenues of $13.84 million, the company …
The article focuses on the "Enterprise value to EBITDA forward" financial metric for Champions Oncology, Inc. (NASDAQ: CSBR). It appears to be a financial data snippet or a specific metric page from TradingView, providing financial information for the company. The content lists various sections …
Champions Oncology, Inc. (NASDAQ: CSBR) generated $59.42 million in revenue last year, primarily from its Pharmacology Services segment, which contributed $57.13 million. The majority of this revenue, $59.42 million, came from operations within the United States. This represents an increase from the previous year's …
This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Champion Iron Ltd (CIAFF) successfully completed the DRPF flotation project on time and on budget, …
Champions Oncology (CSBR) reported record revenue of $59.4 million for fiscal 2026, driven by its Translational Oncology Solutions business, and achieved positive adjusted EBITDA in all four quarters. The company saw services revenue increase by 12% to $58.7 million, with improved gross margins due …
Champions Oncology (CSBR) shares dipped by 10.9% following its Q4 earnings report, despite record revenue growth in fiscal 2026 driven by its core research services. The company experienced an operating loss for the full year but saw narrowed diluted losses per share and improved …
Champions Oncology (NASDAQ:CSBR) has a cash runway of approximately 12 months based on its current cash burn of US$5.0m and cash reserves of US$4.9m as of April 2026. While this short runway is a concern, its revenue grew by 4.4% last year, and its …
This article provides a valuation analysis of Champions Oncology Inc (CSBR), noting its current valuation score of 8.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -31.65, which is significantly below its recent high and above its …
Champions Oncology Inc (CSBR) currently has a financial score of 8.72, ranking 31st out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% year-over-year to 16.56M, while …
Quarterly production of 3.9M wmt, sales of 3.3M dmt, revenues of $357M and EBITDA of $33M1 Initial production of DR quality iron ore from the DRPF project with initial shipment expected in Q2 FY27 Completion of the acquisition of Rana Gruber, a proven high-purity …
Champions Oncology, Inc. provided a tranche update on its equity buyback plan announced on April 5, 2023. From February 1, 2026, to April 30, 2026, the company did not repurchase any shares. However, since the plan's inception, the company has completed the repurchase of …
Champions Oncology, Inc. reported fiscal year 2026 revenue of $59.43 million, a 4.4% increase from the prior year, driven by higher pharmacology services and conversion of delayed studies. Despite revenue growth, the company experienced a net loss of ($1.18M) and diluted EPS of ($0.08), …
Search by ticker symbol or company name and select a result to open its chart.